You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 16, 2025

Portola Pharms Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for PORTOLA PHARMS INC

PORTOLA PHARMS INC has one approved drug.

There are five US patents protecting PORTOLA PHARMS INC drugs.

There are sixty-three patent family members on PORTOLA PHARMS INC drugs in twenty-six countries.

Summary for Portola Pharms Inc
International Patents:63
US Patents:5
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Portola Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 DISCN Yes No 8,404,724 ⤷  Try for Free Y ⤷  Try for Free
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 DISCN Yes No 9,555,023 ⤷  Try for Free ⤷  Try for Free
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 DISCN Yes No 8,404,724 ⤷  Try for Free Y ⤷  Try for Free
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 DISCN Yes No 8,557,852 ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Portola Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 8,691,847 ⤷  Try for Free
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 6,376,515 ⤷  Try for Free
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 6,835,739 ⤷  Try for Free
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 8,518,977 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Portola Pharmaceuticals Inc – Market Position, Strengths & Strategic Insights

In the dynamic and highly competitive pharmaceutical industry, understanding a company's market position, strengths, and strategic insights is crucial for investors, analysts, and industry professionals. This comprehensive analysis delves into Portola Pharmaceuticals Inc, examining its place in the pharmaceutical landscape and uncovering key factors that drive its performance and future prospects.

Company Overview: Portola Pharmaceuticals Inc

Portola Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing novel therapeutics in the areas of thrombosis, hematologic disorders, and inflammation[1]. The company's primary focus has been on developing treatments for life-threatening blood-related disorders and conditions.

Key Products and Pipeline

Portola's product portfolio includes:

  1. Andexxa (andexanet alfa): An FDA-approved antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding[1].

  2. Bevyxxa (betrixaban): An oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for acute medical illness[1].

  3. Cerdulatinib: A dual spleen tyrosine kinase (Syk) and janus kinases (JAK) inhibitor in development for the treatment of hematologic cancers[1].

Market Position and Competitive Landscape

Market Capitalization and Valuation

As of February 2025, Portola Pharmaceuticals has a market capitalization of $1.41 billion USD, making it the world's 4954th most valuable company by market cap[5]. This valuation places Portola in the mid-cap range, indicating a company with significant market presence but still room for growth.

Industry Ranking

Within the pharmaceutical industry, Portola Pharmaceuticals faces competition from both large pharmaceutical giants and smaller, specialized biotech firms. The company's focus on novel therapeutics for blood-related disorders positions it in a niche market with significant potential.

"Portola Pharmaceuticals earns the No. 179 rank among its peers in the Medical-Biomed/Biotech industry group."[6]

This ranking suggests that while Portola is not among the top-tier pharmaceutical companies, it has established a respectable position within its specific industry segment.

Financial Performance and Management Effectiveness

Revenue and Growth

Portola Pharmaceuticals has shown growth in its quarterly revenue, with an 18.9% increase year-over-year in a recent quarter[1]. This growth indicates positive market reception of the company's products and potential for future expansion.

Profitability Metrics

Despite revenue growth, Portola faces challenges in profitability:

  • EPS (Most Recent Fiscal Year): ($4.06)[1]
  • Net Income: ($290,660,000.00)[1]
  • Net Margins: -232.73%[1]

These figures suggest that while the company is generating revenue, it is still investing heavily in research, development, and commercialization efforts, resulting in negative earnings.

Management Effectiveness Ratios

  • Return on Equity (ROE): -267.86%[1]
  • Return on Assets (ROA): -54.66%[1]

These negative ratios indicate that the company is currently not generating profits relative to its equity and assets. However, this is not uncommon for biopharmaceutical companies in the growth and development stages.

Competitive Advantages and Strengths

Innovative Product Portfolio

Portola's focus on developing novel therapeutics for thrombosis and hematologic disorders sets it apart from many competitors. The company's products, particularly Andexxa and Bevyxxa, address critical unmet needs in the market.

Strong Research and Development Capabilities

The company's pipeline, including cerdulatinib for hematologic cancers, demonstrates its commitment to ongoing innovation and potential for future growth[1].

Strategic Collaborations

Portola has established collaboration agreements with major pharmaceutical companies, including Bristol-Myers Squibb, Pfizer, Bayer Pharma, and Janssen Pharmaceuticals[1]. These partnerships provide valuable resources and expertise for product development and commercialization.

Market Opportunities and Growth Potential

Expanding Indications for Existing Products

Portola has the opportunity to explore additional indications for its approved products, potentially expanding their market reach and increasing revenue streams.

Global Market Expansion

While the company has a strong presence in the United States, there is significant potential for expanding into international markets, particularly in Europe and Asia.

Emerging Therapeutic Areas

The company's expertise in blood-related disorders positions it well to explore emerging therapeutic areas and develop new treatments for related conditions.

Challenges and Risks

Intense Competition

The pharmaceutical industry is highly competitive, with numerous companies vying for market share in the thrombosis and hematology spaces. Portola must continually innovate to maintain its competitive edge.

Regulatory Hurdles

As with all pharmaceutical companies, Portola faces significant regulatory challenges in bringing new products to market and maintaining compliance for existing products.

Financial Pressures

The company's current negative profitability metrics highlight the need for careful financial management and potentially raising additional capital to fund ongoing operations and research.

Strategic Initiatives and Future Outlook

Focus on Commercialization

Portola is likely to prioritize the commercialization of its approved products, Andexxa and Bevyxxa, to drive revenue growth and improve profitability metrics.

Pipeline Advancement

Continuing to advance cerdulatinib and other pipeline candidates through clinical trials will be crucial for the company's long-term growth prospects.

Potential for Strategic Partnerships or M&A

Given the company's innovative product portfolio and market position, Portola could be an attractive target for larger pharmaceutical companies looking to expand their presence in thrombosis and hematology.

Comparative Analysis with Competitors

Market Share Comparison

While specific market share data for Portola's products is not provided in the available information, the company's ranking within the Medical-Biomed/Biotech industry group suggests it holds a notable position in its niche market.

Financial Performance Comparison

Compared to some of its peers, such as Corcept Therapeutics (CORT) and Vertex Pharmaceuticals, Portola's financial performance indicates room for improvement[6]. However, the company's focus on novel therapeutics and potential for future growth make it an interesting player in the industry.

Investor Considerations

Risk Profile

Investing in Portola Pharmaceuticals carries significant risks due to its current negative profitability and the inherent uncertainties in drug development and commercialization.

Growth Potential

The company's innovative product portfolio and pipeline offer substantial growth potential, particularly if it can successfully commercialize its products and expand into new markets.

Valuation Metrics

  • P/E Ratio: Not applicable due to negative earnings[1]
  • Price-to-Sales Ratio: Not provided in the available information

Investors should carefully consider these factors and conduct thorough due diligence before making investment decisions.

Key Takeaways

  1. Portola Pharmaceuticals is a mid-cap biopharmaceutical company focused on thrombosis and hematologic disorders.
  2. The company has two FDA-approved products, Andexxa and Bevyxxa, with potential for expanded indications and market reach.
  3. Financial performance shows revenue growth but negative profitability metrics, typical for companies in the growth and development stages.
  4. Competitive advantages include an innovative product portfolio and strong research and development capabilities.
  5. Future growth potential lies in expanding indications, global market expansion, and advancing pipeline candidates.
  6. Challenges include intense competition, regulatory hurdles, and financial pressures.
  7. Strategic initiatives focus on commercialization, pipeline advancement, and potential partnerships or M&A opportunities.

FAQs

  1. Q: What are Portola Pharmaceuticals' main products? A: Portola's main products are Andexxa (andexanet alfa), an antidote for Factor Xa inhibitors, and Bevyxxa (betrixaban), an oral anticoagulant for preventing venous thromboembolism.

  2. Q: How does Portola's market capitalization compare to other pharmaceutical companies? A: As of February 2025, Portola Pharmaceuticals has a market capitalization of $1.41 billion USD, ranking it as the 4954th most valuable company globally.

  3. Q: What are the key challenges facing Portola Pharmaceuticals? A: Key challenges include intense competition in the pharmaceutical industry, regulatory hurdles, and financial pressures due to current negative profitability metrics.

  4. Q: What growth opportunities does Portola have? A: Growth opportunities include expanding indications for existing products, global market expansion, and developing new treatments in emerging therapeutic areas related to blood disorders.

  5. Q: How does Portola's financial performance compare to its competitors? A: While Portola shows revenue growth, its profitability metrics are currently negative. This performance suggests room for improvement compared to some peers, but is not uncommon for companies in the growth and development stages of the pharmaceutical industry.

Sources cited: [1] https://www.marketbeat.com/stocks/NASDAQ/PTLA/ [5] https://companiesmarketcap.com/portola-pharmaceuticals/marketcap/ [6] https://www.nasdaq.com/articles/portola-pharmaceuticals-reaches-80-plus-relative-strength-rating-benchmark-2018-01-10

Last updated: 2025-02-13

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.